Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of BEZ235 versus everolimus in advanced pancreatic neuroendocrine tumors
2012-000769-19Phase 2Terminated
- Sponsor
- Novartis
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in islet cell tumor comparing BEZ235 monotherapy with everolimus monotherapy (2 arms). Primary endpoint: Progression-free survival. Started Aug 2012; status: terminated.
02
Drugs
dactolisibeverolimus
03
Conditions
islet cell tumor
Beyond the preview
Go deeper on 2012-000769-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000769-19.